Gemcovac-19, mRNA vaccine, has Emergency use Authorisation in India against COVID 19.
Gemcovac-19, mRNA vaccine, has Emergency use Authorisation in India against COVID 19
Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, announced that its mRNA vaccine - Gemcovac-19 - against Covid-19 received the Emergency Use Authorization (EUA) from the office of the Drugs Controller General of India (DCGI). Gemcovac-19 is the very first mRNA vaccine developed in India and only third mRNA vaccine to be approved for COVID-19 in the world.
Gennova Biopharmaceuticals Ltd aims to produce around 4 - 5 million doses per month and this capacity can be quickly doubled. Apart from India, Gennova aims to provide access to low-and middle-income countries around the world to the vaccine to blunt the spread of pandemic.
As mRNA vaccines are required to be kept at sub-zero temperatures, it was a mammoth task for Gennova scientists to develop a thermostable mRNA Covid-19 vaccine. Scientists had to innovate to suit local needs to make it affordable and deployable. The new vaccine can now be stored at the temperature of a standard medical refrigerator.